Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells

BACKGROUND: Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8(+) T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigen...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Masterman, Kelly-Anne, Haigh, Oscar L, Tullett, Kirsteen M, Leal-Rojas, Ingrid M, Walpole, Carina, Pearson, Frances E, Cebon, Jonathon, Schmidt, Christopher, O'Brien, Liam, Rosendahl, Nikita, Daraj, Ghazal, Caminschi, Irina, Gschweng, Eric H, Hollis, Roger P, Kohn, Donald B, Lahoud, Mireille H, Radford, Kristen J
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Clinical/Translational Cancer Immunotherapy
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7394304/
https://ncbi.nlm.nih.gov/pubmed/32737142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000691
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki